MET and prostate cancer: Furthermore, we conducted the overexpression of exogenous MET in prostate cancer cell lines LNCaP and 22RV1 to reach olaparib‐resistance states, and following treatment with olaparib or crizotinib alone or a combination of the two, then detected the expression of PI3K/AKT by western blot.